ERBB2 and aneurysmal bone cyst: The MONARCH 2 and MONARCH 3 Japanese subpopulation analyses add to the limited information available on abemaciclib in Japanese patients, indicating that abemaciclib/ET therapies are efficacious in either the first- or second-line setting in HR+, HER2− ABC.